Demonstrating efficacy in rat adjuvant-induced arthritis (with an ED50 of 2.7 mg/kg, administered twice daily orally) and rat collagen-induced arthritis (ED50 of 1.6 mg/kg, BID, PO) disease models, AS2444697 reveals good bioavailability in pharmacokinetic studies conducted on rats (F% 50) and dogs (F% 78)^[1].

In LPS/GalN-treated mice, AS2444697, administered at doses ranging from 0.3 to 3 mg/kg, significantly elevates plasma levels of IL-1β, IL-6, TNF-α, MCP-1, and aminotransferases (ALT and AST). A single administration of AS2444697 dose-dependently reduces the plasma levels of these parameters, with significant effects observed at doses of 1 mg/kg or higher^[2].

Following oral administration to 5/6 nephrectomized (Nx) rats at a dose of 3 mg/kg, the peak plasma and tissue (liver and kidney) concentrations of AS2444697 are observed at 1 hour, gradually decreasing thereafter, with a terminal half-life of approximately 2.7-2.9 hours^[2].